IMU looked into iNKT as Hopper originally licenced it to ALA. But the colab was terminated for possibly 3 reasons:
1. iNKT did not work or wasn't helpful for IMU's goals. 2. iNKT worked well but the focus was rather on Azer-Cel than iNKT for financial reasons, but that wouldn't have caused a termination, maybe just a postponing. 3. iNKT worked well but not considered to be commercially sensible for IMU for financial reasons.
No idea, time will tell once ALA gets their trials going. But they have faced a lot of obstacles, still waiting to get their IND from the FDA. Current expectations early next year if they get their homework done.
IMU Price at posting:
4.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)